Correction to: The Clinical Utility of DCISionRT on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery.
作者信息
Shah Chirag, Bremer Troy, Cox Charles, Whitworth Pat, Patel Rakesh, Patel Anushka, Brown Eric, Gold Linsey, Rock David, Riley Lee, Kesslering Christy, Brown Sheree, Gabordi Robert, Pellicane James, Rabinovich Rachel, Khan Sadia, Templeton Sandra, Majithia Lonika, Willey Shawna C, Wärnberg Fredrik, Gerber Naamit K, Shivers Steve, Vicini Frank A
机构信息
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
PreludeDx, Laguna Hills, CA, USA.
出版信息
Ann Surg Oncol. 2021 Dec;28(Suppl 3):878. doi: 10.1245/s10434-021-10138-3.
Abstract
摘要
相似文献
1
Correction to: The Clinical Utility of DCISionRT on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery.对《DCISionRT在保乳手术后导管原位癌患者放疗决策中的临床应用》的更正
Ann Surg Oncol. 2021 Dec;28(Suppl 3):878. doi: 10.1245/s10434-021-10138-3.
2
Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment.生物标志物 DCISionRT 在 DCIS 治疗中的成本效益分析。
Clin Breast Cancer. 2021 Jun;21(3):e271-e278. doi: 10.1016/j.clbc.2020.10.007. Epub 2020 Oct 24.
3
Validation of a Ductal Carcinoma Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy.保乳手术联合或不联合放疗后导管癌复发风险生物标志物谱的验证
Clin Cancer Res. 2020 Aug 1;26(15):4054-4063. doi: 10.1158/1078-0432.CCR-19-1152. Epub 2020 Apr 27.
4
Factors associated with residual disease after initial breast-conserving surgery for ductal carcinoma in situ.与导管原位癌初始保乳手术后残留病变相关的因素。
Hum Pathol. 2012 Jul;43(7):986-93. doi: 10.1016/j.humpath.2011.09.010. Epub 2012 Jan 4.
5
Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ.DCISionRT用于指导导管原位癌治疗的成本效益分析
JNCI Cancer Spectr. 2020 Jan 31;4(2):pkaa004. doi: 10.1093/jncics/pkaa004. eCollection 2020 Apr.
6
Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.保乳手术及乳腺导管原位癌（导管内癌）根治性放疗后局部复发的挽救性治疗。
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):3-9. doi: 10.1016/0360-3016(94)90512-6.
7
Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?保乳手术后原位导管癌的放射治疗：是或否？
Chirurgia (Bucur). 2017 Jul-Aug;112(4):403-412. doi: 10.21614/chirurgia.112.4.403.
8
[Ductal carcinoma in situ treated with radiation therapy and additional boost].经放射治疗及追加剂量照射治疗的导管原位癌
Cancer Radiother. 2015 May;19(3):175-9. doi: 10.1016/j.canrad.2015.01.002. Epub 2015 Apr 25.
9
Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy.导管原位癌多灶性的意义：保乳治疗女性的结局
J Clin Oncol. 2007 Dec 10;25(35):5591-6. doi: 10.1200/JCO.2007.11.4686. Epub 2007 Nov 5.
10
Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age.保乳手术治疗导管原位癌女性的长期随访：年龄的影响
Cancer. 1999 Nov 1;86(9):1757-67. doi: 10.1002/(sici)1097-0142(19991101)86:9<1757::aid-cncr18>3.0.co;2-v.
引用本文的文献
1
Benefits and harms of breast cancer screening revisited: a large, retrospective cross-sectional study quantifying treatment intensity in women with screen-detected versus non-screen-detected cancer in Australia and New Zealand.重新审视乳腺癌筛查的利弊：一项大型回顾性横断面研究，量化澳大利亚和新西兰筛查发现与未筛查发现癌症的女性的治疗强度。
BMJ Oncol. 2023 Dec 21;2(1):e000100. doi: 10.1136/bmjonc-2023-000100. eCollection 2023.
2
Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma .用于预测乳腺导管癌复发风险和放射治疗获益的7基因生物标志物的分析验证
Front Oncol. 2023 May 19;13:1069059. doi: 10.3389/fonc.2023.1069059. eCollection 2023.
Zotero 插件